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Summary Rhenium (I)-diselenother (Re-diselenoether) is a water soluble metal-based compound, 
combining one atom of rhenium and two atoms of selenium. This compound has been reported to 
exhibit marked activities against several solid tumor cell lines. We now disclose an improved 
synthesis of this complex. The Re-diselenoether showed a potent inhibitory effect on MDA-MB231 
cell division in vitro, which lasted when the complex was no longer present in the culture. Re-
diselenoether induced a remarkable reduction of the volume of the primitive breast tumors and of the 
pulmonary metastases without clinical signs of toxicity, in mice-bearing a MDA-MB231 Luc+ tumor, 
orthotopically transplanted, after a daily oral administration at the dose of 10 mg/kg/d. Interestingly, 
an antagonism was observed when cisplatin was administered as a single i.p. injection one week after 
the end of the Re-diselenoether administration. In an effort to gain insight of the mechanisms of action 
of Re-diselenoether complex, interaction with 9-methylguanine as a nucleic acid base model was 
studied. We have shown that Re-diselenoether gave both mono- and bis-Re-guanine adducts, the 
species assumed to be responsible for the DNA intrastrand lesion.   
Keywords Rhenium . Selenium . Breast cancer . MDA-MB231 cell line . Bioluminescence 
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Introduction   
Metal-based drugs have received increasing attention in recent years. The use of metals is indeed very 
attractive, as they offer unique spectrum of reactivity through ligand exchange and redox processes 
that is not available in the more common organic-based drugs. The discovery of the anticancer 
properties of cisplatin during the 1960s spurred the quest for alternative anticancer drugs with less 
side-effects. Beside platinum analogues including platinum (II) and (IV) derivatives, other metals have 
been recently explored, such as gallium, ruthenium, iron, gold, titanium or palladium [1]. In this 
context, rhenium-based drugs appeared as promising candidates for clinical development. Over the 
past years a growing number of studies have recently revealed the potential of Re organometallic 
complexes as anti-cancer agents. A recent review has been published with a particular emphasis on the 
cellular uptake and the localization of the currently known Re organometallic complexes as well as 
their potential mechanism of action [2]. Among Re organometallic complexes, several rhenium 
carbonyl complexes have been found to display cytotoxicity against breast cancer cell lines. For 
example, a Re(tricarbonyl)pentylcarbonato compound able to fight triple node negative human breast 
cancer cell lines has been described [3]. Nevertheless, despite the design of very efficient potent anti-
cancer agents, very few in vivo studies have been conducted on cold Re organometallic complexes. On 
the other hand, it is noteworthy that some selenium-based drugs have demonstrated a selective 
cytotoxicity against cancerous cells [4-6]. The tumor-specific cytotoxic effects of selenium, with 
special emphasis on cascades of cellular events induced by pharmacologically active selenium 
compounds have been recently reviewed [7]. It appears that certain redox-activated selenium 
compounds induce complex cascades of pro-death signaling at pharmacological concentrations with 
superior tumor specificity, and that the target molecules are often implicated in drug resistance. With 
the aim to combine the antiproliferative properties of rhenium with the unique apoptotic modulator 
properties of selenium we have recently designed the rhenium(I)-diselenoether complex 1 in which a 
central inorganic rhenium atom is coordinated by two selenium atoms. Complex 1 was shown to 
exhibit remarkable cytotoxicity against MCF-7 breast cancer cell lines [8]. The uptake and efflux of 
Re in malignant cells exposed to complex 1 have been reported, together with evidence of the 
incorporation of Re into the nucleus. Furthermore, tissue distribution of Re and selenium (Se) after 
oral administration of 1 to mice have been reported [9].  
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Fig. 1  Chemical structure of complex 1  
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The purpose of the present paper was to report the activity of rhenium-diselenother complex 1 (Fig. 1) 
in experimental models of human breast tumor toward highly metastatic MDA-MB231 cancer cells in 
culture, and in MDA-MB231 Luc+ tumors transplanted in mice. The interaction of 1 with 9-
methylguanine is also described, providing evidence that interaction of 1 with DNA might be involved 
in the mechanism of action of 1 at the molecular level. 
Material and Methods 
Chemical protocols  
Although the published synthesis of complex 1 has proved rather efficient, the elaboration of a key 
intermediate (compound 4 in scheme 1) was somewhat problematic, since suffering from a vexing 
lack of reproducibility. For that reason, we have recently developed an alternative approach to key-
compound 4, which has proved perfectly reproducible. This new protocol involved the alkylation of 
the disodium salt of propane-diselenocyanate 2 with bromoacetic acid methyl ester, giving diester 3, 
which was next saponified with lithium hydroxide into diacid 4. Complexation of ReCl(CO)3 by 
diselenoether 4, followed by sodium bicarbonate treatment provided complex 1, as previously reported 
[8]. Likewise, to study the possible interactions of the complex with DNA bases without competitive 
attack of the carboxylate appendages on the Re atom, the corresponding dimethyl ester complex 5 was 
prepared by condensation of diselenoester 3 with ReCl(CO)3 in 68% yield.  
Alternative synthesis of key intermediate: Preparation of (3-carboxymethylselanyl-propylselanyl)-
acetic acid dimethyl ester (compound 3): To a solution of 1,3-bis-selenocyanato-propane 2 (1.0 g, 3.96 
mmol) in absolute ethanol (20 mL) was added bromoacetic acid methyl ester (1.23 g, 8.0 mmol). The 
mixture was stirred under nitrogen until complete dissolution. Sodium borohydride (303 mg, 8.0 
mmol) was then added in one portion. The reaction mixture was stirred at room temperature for 16 h. 
The white precipitate was filtered of on a sintered glass funnel and the paint yellow filtrate was 
concentrated under reduced pressure to leave 3 as a pale yellow oil (1.12 g, 82%); 
1
H NMR (CDCl3): δ 
3.72 (s, 6H, OCH3), 3.17 (s, 4H, CH2CO2Me), 2.82 (t, J = 7.2 Hz, 4H, SeCH2CH2CH2Se), 2.0 (quint, J 
= 7.2 Hz, 2H, SeCH2CH2CH2Se). 
Preparation of (3-carboxymethylselanyl-propylselanyl)-acetic acid (compound 4): To a solution of 
compound 3 (692 mg, 2.0 mmol) in THF (3 mL) and methanol (1 mL) was added a solution of 
LiOH.H2O (336 mg, 8.0 mmol) in 2 mL of water. The reaction mixture was stirred at room 
temperature for 16 h and the solvents were removed under reduced pressure. 3N HCl was added until 
to pH = 1, and the mixture was extracted with ethyl acetate. The combined organic layers were dried 
over MgSO4 and concentrated under reduced pressure. The oily material was taken into a small 
amount of CH2Cl2 and precipitate with petroleum ether. The solid was filtered, washed with diethyl 
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ether, and dried under vacuum to give 540 mg (85% yield) of compound 4, which was unequivocally 
identified by comparison with an authentic sample.  
Synthesis of dimethyl ester complex 5: Preparation of rhenate (tricarbonylchloro[2, 2'-[1, 3-
propanediylbis(carbomethoxymethylseleno-)]])  (5): A mixture of diselenoester 3 (216 mg, 0.62 
mmol) and ReCl(CO)3 in  THF (20 mL) was heated at 60 °C for 16 h. The mixture was cooled to room 
temperature and concentrated under reduced pressure to leave crude 5. Purification by chromatography 
over silica gel gave 5 as a colorless oil (278 mg, 68%); 
1
H NMR (C6D6): The presence of 
stereoisomers induced splitting of most signals δ 3.61 (dd, J = 14.1, 4.5 Hz, 1H), 3.42 (dd, J = 14.1, 
6.9 Hz, 1H), 3.35-3.24 (m, 6H), 3.16-3.06 (m, 0.5H) , 2.99 (d, J = 13.8 Hz, 1H), 2.86 (m, 0.5H), 2.55-
2.28 (m, 2 H), 1.5-1.2 (m, 4H). 
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Scheme 1: Synthesis of 1 with optimized approach to key-intermediate 4. Reagents and conditions, i: 
BrCH2CO2Me, NaBH4, EtOH, 16 h, 20 °C (82%); ii: LiOH.H2O, THF, MeOH, 16 h, 20 °C (85%); iii: 
ReCl(CO)5, THF, reflux, 16 h (72%); iv: 2.0 equiv. NaHCO3, MeOH,H2O, 0 °C (90%); v: ReCl(CO)5, THF, 
reflux, 16 h (68%). 
Interaction of rhenium diseleno-ester 5 with 9-methylguanine: To a solution of complex 5 (139 mg, 
0.21 mmol) in methanol (4 mL) was added dropwise a solution of AgBF4 (42 mg, 0.21 mmol) in 
methanol (1 mL). A sticky precipitate formed immediately. The reaction mixture was stirred at 15 °C 
for 16 h and filtered. The filtrate was added to a solution of 9-methylguanine (35 mg, 0.21 mmol) in 
1:1 water: methanol mixture (24 mL). The reaction mixture was stirred for 3 d at 15 °C and 
concentrated under reduced pressure (1 mm Hg) at 20 °C. The obtained solid was washed with 
methylene chloride to remove any trace of free ligand and dried. Mass spectra analysis ESI (+) showed 
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four components: m/z = 782.0 [C18H23N5O8ReSe2]
+
; 616.9 [C12H16O7ReSe2]
+
; 601.1 [C15H14N10O5Re]
+
; 
435.9 [C9H7N5O4Re]
+. 
Ions m/z = 782.0
 
and m/z = 616.9 showed the characteristic isotopic pattern of 
the ReSe2 fragment, whereas ions m/z = 601.1 and m/z = 435.9 ions displayed a more simple profile 
corresponding to a rhenium complex devoid of the diselenoether ligand.  
Morphological and inhibitory effects on MDA-MB231 breast cancer cells  
Cell lines. MDA-MB-231 (Passage No. 13) breast cancer cell lines were kindly provided by Dr. S. 
Fraser and Pr. M. Djamgoz at Imperial College, London. Cells were grown as adherent monolayers in 
Dulbecco's Modified Eagle Medium (Sigma), supplemented with 5% Fetal Bovine Serum and phenol 
red. Cultures were maintained at 37 °C with a humidified atmosphere containing 5% CO2 and were 
passaged using 0.25% trypsin in DPBS (PAA) when they reached 80% confluency. Cell number was 
established via haemocytometer count after dead cell exclusion using trypan blue.  
In vitro toxicity. MDA-MB231 cells were seeded on 48-well plates at 5×10
4
 cells/well, allowed 
forming an adherent monolayer overnight and then exposed to the indicated concentrations of Re-
diselenoether complex for 48 hours. Cells were then washed and incubated with Re-diselenoether-free 
medium for a further 48 hours. The effects of Re on cell viability was determined at the indicated time 
using haemocytometer count of live cells under light microscopy and via flow cytometry. 
Proliferation Prior to Re treatment, MDA-MB231 cells at the concentration of 1×10
6
 /mL in PBS were 
labelled with 0.5 M of violet dye (CellTrace violet Invitrogen) for 20 min at 37 °C. The intensity of 
fluorescence of the violet dye was acquired on an LSRFortessa flow cytometer (BD) and analyzed 
with FlowJo version 9.3.1 (TreeStar, Ashland, OR, USA). Dose responses over time were analysed 
using GraphPad Prism software version 5.03 (GraphPad Software Inc.). 
Animal study design: Oral administration of rhenium(I)-diselenoether complex 
This study was performed in Cellvax laboratory. In this study, one of the objectives was to look for a 
synergism between cisplatin and Re (I)-diselenoether [10]. Hormone-independant breast cancer MDA-
MB231 cells (origin: ATCC#HTB-26
TM
), transfected with the luciferase gene (Luc+) were 
orthotopically implanted into the mammary gland (fat pad) in athymic nu/nu nude mice (Charles 
River, France). With a cell viability of about 97%, 1.0 × 10
6
 cells per mouse were injected in a volume 
of 50 μl/mouse. The animals were 5 to 6-week-old female, of about 20 g each, and specific and 
opportunistic pathogen free. They were acclimatized for at least seven days before the initiation of the 
designed study. A total of 30 mice were used for this study. Animals were housed in individual 
polyethylene cages, in a climate and light-controlled environment. All animals were kept under 
environmentally controlled housing conditions: lights on between 7:00 AM to 7:00 PM; temperature 
inside of the animal facility strictly maintained at 21 + 1 °C; relative humidity of 70% throughout the 
entire study period, and maintained in accordance with Cellvax approved standard operation 
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procedures (SOP) and with local Ethical Committee approval. Animals were fed with commercially 
available rodent food (Safe, Les Tremblats, Augy, France). Water (sterilized water) was available ad 
libitum. 
Animals were numbered and given a unique animal identification ear notch mark. Ethical manager. A 
Ph.D. and Veterinary Doctor at Cellvax company assumed the function of ‘Ethical Manager’ within 
this project. Experimental groups. Three groups of 10 mice each for a total of 30 mice were treated. 
Measurable mammary tumors were observed in 18 mice at day 9 after the inoculation of the tumor 
cells, while no mammary tumors were observed in 12 mice. Groups were then homogeneized to have 
6 mice with a measurable tumor in each group. Group 1: Cisplatin (CDDP) group: mice were treated 
with CDDP as a single intraperitoneal (IP) injection at a dose of 6 mg/kg on day 41 after the 
inoculation of the tumor cells; Group 2: Re (I) - diselenoether complex group (Re drug group): mice 
were daily orally treated with Re - diselenoether complex at the dose of 10 mg/kg/24 h for four weeks, 
from day 9 to day 36 after the inoculation of the tumor cells; Group 3: Re (I) - diselenoether complex 
and CDDP group (combined drug group): mice were daily orally treated with Re-diselenoether 
complex at the dose of 10 mg/kg/24 h for four weeks, from day 9 to day 36 after the inoculation of the 
tumor cells (as in group 2) and then with CDDP as a single intraperitoneal (IP) injection at a dose of 6 
mg/kg on day 41 (as in group 1).  
Oral administration of the Re compounds: The Re treatments were started on day 9 after the 
inoculation of the tumor cells. They were orally administered in the food instead of gavage, as it is a 
less stressful alternative to oral gavage [11]. Transwean was used to prepare capsules in which the Re 
(I)-diselenoether was incorporated. The capsules were prepared the day before treatment by mixing 1g 
of transwean powder (feed rodent form of powder mixed with water forms a sort of jelly) and 1 mL of 
water. The mixture was then placed in the wells of a 24-well plate and placed in the refrigerator. The 
next day, the capsules were removed from the mold with a spatula and then cut into small pieces. Re 
drug at a dose of 10 mg /kg was diluted in a volume of 50 μl and introduced into one of the pieces of 
"capsule" with a syringe, then that piece was placed in the mouse cage. Once the capsule containing 
the treatments were consumed normal food pellets were put into the cage until evening. This mode of 
administration is simple and effective. The treatments were completely consumed with no risk of 
overdose. Toxicity evaluation. Determination of body weight was performed twice a week for each 
mouse. Anti-tumor effect. The tumor growth was measured (tumor length, width and volume) twice a 
week by using an external caliper. The mean tumor volumes [MTV; MTV + (SD); MTV + (SEM)] 
were estimated. The tumor growth data was recorded for each individually identified mouse. Tumor 
volume was calculated by using the following formula : V = length x width²/2. An imaging by 
bioluminescence was performed in 2 mice of each group on days 44, 51 and 58 after the inoculation of 
the tumor cells. The mice were selected to have comparable tumors on day 44.  
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Statistics: Statistically evaluation of the antitumor effect was assessed by ANOVA test (One way 
Anova on the ranks).  
Results and discussion 
Design and synthesis of Re-diselenoether 1 
Critical to the antitumor activity of pseudo-symmetric complex 1 was the presence in its framework of 
a central inorganic core, in which a heavy metal atom (Re) is coordinated to two semi-metal atoms 
(Se). The chemical/biological considerations which have governed the design of this three-metal core 
scaffold were disclosed hereafter. A major interest of Re is related to its very low mammalian toxicity; 
it has thus been evoked that Re is "one of the least toxic of the metallic elements"[12]. This low 
toxicity, quite surprising for a heavy metal, can be tentatively interpreted on the basis of its seven 
degrees of oxidation state (1 to 7) that could authorize subsequent oxidative detoxification processes. 
Only few data exist on the metabolism of Re compounds. However, a study of the metabolism of 
[
188
Re(CO)3(carboxycyclopentadienyl)] in mice revealed the high plasma stability of this Re 
compound [13]. This study also suggested that the organometallic core of this complex remained 
unchanged under biological environment. In full agreement with this assertion, the Re compound was 
essentially excreted as glycine conjugate via the renal route, without further metabolism. 
Regarding the presence of two Se atoms in complex 1, it should be mentioned that, fueled by decades 
of animal studies, Se could significantly reduce the incidence of cancer. This topic is now an area of 
intense worldwide study [14]. Nevertheless, although inorganic Se has been shown to inhibit 
carcinogenesis, there is a concern about toxicity, since chronic feeding of inorganic Se (e.g. selenites 
or selenates) at levels of > 5 ppm is toxic in rodents. However, on the basis of the pioneering work of 
El-Bayoumy et al. [15-17] and Sanmartin et al. [18-20], a series of synthetic Se compounds have been 
elaborated, in which the Se atom is doubly substituted by carbon atoms, as in complex 1. These 
compounds have proved to be notably more potent and much less toxic than the inorganic 
counterparts. In contrast to Re compounds, the metabolism of Se compounds in mice is well-
documented. It was found that Se compounds which included the RCH2SeCH2R pattern in their 
structure, such as complex 1, were first cleaved via the trans-selenation pathway into RCH2SeH 
metabolite that, in turn was converted into H2Se through the β-lyase dealkylation reaction. Both H2Se 
and are CH3SeH are thought to be pivotal metabolites in Se-mediated cancer chemoprevention [7]. A 
last comment should be made on the design of 1. Since the advantage of all ionic compounds over 
neutral species is their improved solubility in water, which markedly facilitates their application in 
biological systems, precursor 2 was ornamented at the Se-levels with two acetic acid moieties [2→4]. 
At the last step of the synthesis the two carboxylic acid functions were ultimately converted into 
water-soluble disodium salt 1 (Scheme 1).  
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The new procedure of synthesis of compound 1 was simple, reproducible giving a stable product 
easily authenticated through its IR spectrum. The presence of d
6
 fac-[Re(CO)3)]
+
 moiety in complex 1 
could explain its high chemical stability. This complex is amphiphilic, soluble in water, and then will 
be easy to administer. It also possesses lipophilic properties that allow a facile diffusion across cell 
membranes and a good biodistribution. 
 
Interaction of rhenium complex 1 with 9-methylguanine. 
Extensive studies with many [Re(CO)3] complexes indicate that their cytotoxicity is due to the 
formation of 1,2-intrastrand adducts e.g. between  the N-7 atom of two adjacent guanine residues in 
DNA, in a fashion similar to cisplatin. Likewise, rhenium accumulation in cell nucleus treated with 
Re-diselenoether 1 suggested a possible interaction  with nucleic acids [9]. In order to probe such 
binding with complex 1, we have investigated the reaction of 5 with 9-methylguanine (9-MeG) as 
simple surrogate of the guanine base in DNA. Indeed, Zobi et al. had previously reported that the 
[Re(CO)3]
+
 cation bound to 9-MeG to give mono or bis-adducts [21,22]. Thus, reaction of 5 with 
silver fluoroborate gave the corresponding cation which was further reacted with 1 equiv. of 9-MeG in 
methanol/water mixture. Analysis of the obtained mixture by mass spectrometry indicated that mono-
adduct [Re(CO)3(C9H16Se2O4).9-MeG]
+
 BF4
-
 was indeed formed as a minor component (10-15%). 
Interestingly, the major product turned out to be the bis-adduct [Re(CO)3(9-MeG)2(H2O)]
+
 BF4
-
, 
previously observed by Zobi. The isotopic profiles of both ions are in full agreement with the 
predicted patterns for the proposed molecular formula (Fig. 2).  In addition, the infrared spectrum 
revealed characteristic CO vibrations at 2027, 1915 and 1895 cm
-1
 previously reported for a 9-MeG 
bis-adduct [21]. These observations clearly indicated that the bis-selenoether ligand could be easily 
displaced by nucleic acid bases to provide guanine bis-adducts, suggesting that the Re-diselenoether 
complex 1 would be able to form intrastrand lesions. We may hypothesized that in biological medium, 
following initial aquation, the intermediate rhenium cation is able to react with nucleic acid bases in 
nucleus to give mono-adduct (Ion A, Fig.2).  The constraint nature of the latter probably facilitated the 
exchange of the weakly chelating diselenoether ligand by water to give a very reactive ion (Ion D, 
Supplementary Figure 1). Finally, a second nucleic acid base addition can easily take place to give 
1,2-intrastrand adducts, whereas the liberated seleno ligand would probably diffuse back to the 
cytoplasm. 
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Fig. 2  Observed (bottom) and predicted (top) isotopic patterns of 9-methylguanine mono-adduct ion 
[Re(CO)3(C9H16Se2O4).9-MeG]
+ 
(A) and bis-adduct [Re(CO)3(9-MeG)2(H2O)]
+
 (B).  
 
Antitumor effect in vitro of the Re-diselenoether complex 1 
It was earlier shown that MCF-7 breast malignant cells were more sensitive to the Re-diselenoether 
complex 1 than A 549 lung cancer cells and HeLa cervix carcinoma cells [9]. We therefore 
investigated malignant cells derived from a human breast carcinoma, the hormone-independent MDA-
BB231 cells for the morphological and inhibitory effects of the Re-diselenoether complex.  
In the presence of a low concentration of Re (I)-diselenoether complex (10 μM), modifications in cell 
shape and morphology were clearly visible (Fig 3A) when compared to untreated cells. These cellular 
alterations corresponded to a reduction in size and a loss of adherence indicating that treated cells were 
no longer proliferating and possibly included apoptotic cells. Further analysis was performed using 
Flow cytometry where Forward Scatter (FSC) and Side Scatter (SSC) parameters correspond to 
measurements of cell size (FSC) and granularity (SSC) (Fig 3B). Cellular and nuclear debris generated 
by dead cells were characterized by low FSC/SSC values (< 30 K) and excluded from the live gate. 
Upon 48 h exposure to Re, only 65.1% of Re-treated cells were identified as alive compared to 92.1% 
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in the untreated condition. This heterogeneous population included cells of low FSC, indicative of 
non-proliferative cells, and cells of high SSC, indicative of granular apoptotic cells, which supported 
the microscopic observations (Fig 4A). 
 
Fig 3  (A) Light microscopy images (5x objective) and (B) Flow cytometry dot plots comparing 
MDA-MB231 cells that have been exposed or not to 10M of the Re-diselenoether complex for 48h 
One of the hallmarks of cancer cells is their dysregulated proliferation. To further evaluate the effect 
of the Re complex on tumor cell ability to proliferate, MDA-MB231 cells were cultured for 48 h in the 
presence of 10 μM of Re complex, and for an additional 48 h in Re-free medium. A cell trace violet 
dye was used to label the cells prior exposure to Re and fluorescence intensity was analysed by flow 
cytometry (Fig 4A). Labeled cells at d0 showing maximal fluorescence intensity (shaded red 
histogram) and unlabeled cells (shaded blue histogram) were used as controls. As expected, untreated 
MDA-MB231 cells showed cell divisions characterized by a reduction in violet dye fluorescence 
intensity at d2 and an even greater reduction at day 4 (upper panel). Interestingly, MDA-MB231 cells 
Untreated Re-diselenoether 10M 
SSC 
A 
B 
Untreated Re-diselenoether 10M 
 FSC 
 11 
treated for 48 h with Re showed a reduction in fluorescence intensity at d2, yet to a lesser extent than 
untreated cells (lower panel). Most importantly, there was no further reduction at d4 indicating no 
further proliferation. These data show that the Re complex had a negative impact on cell division 
within the 48 h of culture; this inhibition was not reversed by the absence of Re in the culture beyond 
48 h. 
Cell division was also quantified by standard cell counts at d2 and d4 of culture with 10 μM and 50 
μM of Re complex (Fig 4B). Exposure to a concentration of 50 μM of Re complex had a striking 
effect on cell proliferation showing a total inhibition of cell division as early as 48h which lasted after 
removal of the Re complex. In line with the flow cytometry experiment (Fig 4A), the lower 
concentration of 10 μM of Re-drug was effective to slow down cell proliferation within 48 h of culture 
and prevented the cells to proliferate further beyond that time point. Altogether, these data show that 
the Re-diselenoether complex is a potent inhibitor of tumor cell division at low concentration and that 
this effect is sustained even when the complex is no longer present in the culture. 
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Fig. 4  (A) Flow histograms of MDA-MB231 cells untreated or treated with 10 M Re and analyzed 
for violet fluorescence intensity at the indicated time points. Plots show histograms of unlabeled 
control cells (shaded blue), cells labeled with violet dye at d0 prior culture (shaded red) and cells with 
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decreasing amount of violet dye at d2 (green) and d4 (orange) due to a dilution of the violet dye upon 
cellular division. Data are representatives of 3 independent experiments. (B) Average fold increase in 
cell number over 4 days of culture in the presence of 0, 10 or 50 M of Re complex. Data represents 
the mean ± SEM values pooled from 2 independent experiments. 
Potential targets of the rhenium diselenoether complex 1 
It has been reported that Re-based drugs could target more specifically the malignant cells than the 
healthy cells [2,23] . On the other hand, it is noteworthy that some Se-based drugs have demonstrated 
a selective cytotoxicity against cancerous cells [4-6]. The tumor-specific cytotoxic effects and the 
cascades of cellular events induced by the major groups of pharmacologically active selenium 
compounds have been reviewed [7]. It is clear that certain redox-active selenium compounds induce 
complex cascades of pro-death signaling at pharmacological concentrations with superior tumor 
specificity, and that the target molecules are often implicated in drug resistance. This review also 
emphasized on the chemotherapeutic applications of Se with multi-target attacks on tumor cells, and 
moreover on the great pharmacological potential of Se for the treatment of resistant cancers. 
The rhenium  capture was previously studied in the nucleus of three human breast cancer cells [9]: 
MCF-7s (sensitive cells), MCF-7R (resistant cells) and MCF-7 MDR (multidrug resistant cells) were 
exposed to the Re-diselenoether drug at the dose of 400 μM for 48 h (uptake), followed by a post-
exposure period of 48 h (efflux). The next intra-nuclear Re concentrations (μM/106 cells) were 
recorded: MCF-7s: 0.08 (uptake), 0.25 (efflux), MCF-7R: 0.25 (uptake), 0.12 (efflux) and MCF-7 
Mdr: 0.15 (uptake), 0.09 (efflux). Regarding the uptake of Re, the concentration in the nucleus was 
less important in the MCF-7s sensitive cells than in the other cell types. However, in MCF-7R and in 
MCF-7 MDR, which are MCF-7 cells with an acquired resistance of cytotoxic agents, the nucleus 
concentration in Re notably decreased after the post-exposure period, indicating an efflux of Re out of 
the nucleus. This observation is of critical importance regarding the therapeutic protocol. Indeed, with 
the aim of overcoming the dramatic consequences of a Re efflux in these cells, it appeared necessary 
to maintain a continuous exposure of the malignant cells to the drug; this may be achieved through a 
daily oral administration. 
 
Antitumor effect of the rhenium-diselenoether 1 in MDA-MB231 tumor-bearing mice 
It is known that liposomal rhenium cluster compounds potentiate a platinum-based chemotherapy [23-
26]. For that reason, we decided to investigate a potential synergism between cisplatin and the Re-
diselenoether complex in our experimental model with transplanted MDA-MB231 Luc+ human breast 
tumor in mice. Three groups were thus compared: Group 1, treatment by cisplatin (control); group 2, 
treatment with Re-diselenoether complex; group 3, treatment by Re-diselenoether complex + cisplatin. 
Re-diselenoether complex showed remarkable antitumor effects versus cisplatin based chemotherapy 
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in mouse model of breast cancer. The volume of the primitive tumor was remarkably reduced in mice 
treated with Re-diselenoether complex versus those treated by cisplatin, taken as a control group (p = 
0.0006). Results are depicted in Fig. 5 and in Table 1 (Supplementary Table1).  
 
 
Fig. 5  Volume of the tumors after the inoculation of the cancer cells. Group 1: treatment by cisplatin 
(control); group 2: treatment with Re-diselenoether complex; group 3: treatment by Re-diselenoether 
complex + cisplatin. 
 
A first divergence between the three curves was observed on d16, that is to say, two weeks after tumor 
grafting. In group 1 (mice treated with a single administration of cisplatin on d41), a regular tumor 
volume increase was recorded at the d16-d67 interval, with a final volume reaching up to 140 mm
3
. 
Regarding group 2 (mice treated daily with the Re drug from d9 to d36), a plateau was observed at the 
d16-d47 interval, with a final volume reaching up to 20 mm
3
, followed by a complete regression of the 
tumors at the d51-67 interval. In group 3 (mice treated with the Re drug according to group 2 protocol, 
combined with a single administration of cisplatin on d41), the tumor volumes approximatively 
matched those of group 2 until cisplatin administration, followed by a rapid increase until d67, with a 
final volume reaching up to 180 mm
3
. These observations deserve the following comments. The 
absence of any significant inflexion in the profile of curve 1 after cisplatin administration clearly 
reflected a lack of antitumor activity of this Pt-drug toward MDA-MB231 tumor-bearing mice with 
this schedule of treatment. By contrast, the profile of curve 2 revealed a nearly immediate antitumor 
effect of the Re drug, and a complete cure of the tumors after a one-month drug exposure, followed by 
a post-exposure period of 2 to 3 weeks. Examination of the profile of curve 3 is of a peculiar interest 
regarding the mechanistic aspect of Pt-drugs and Re-drugs. Indeed, to our great surprise, a deleterious 
effect was observed when Re drug 1 was co-administered with cisplatin, namely a dramatic collapse of 
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the antitumor activity. This phenomenon can be interpreted on the basis of the binding modes of these 
metal-based drugs to DNA nucleotides. On this basis, one can argue that a Pt-drug could irreversibly 
displace the Re-drug from a pre-existing DNA-adduct. This assertion was reinforced through the 
consideration that both Re-drugs and Pt-drugs target the same recognition sites in DNA bases, 
exemplified by the N7 center of guanine.  
 
Bioluminescence imaging in mice. .The imaging by bioluminescence (Institut Gustave Roussy, France) 
illustrated the effects of Re (I)-diselenoether complex on the tumor activity (Fig. 6). In the group of 
the two mice (S1 and S2) treated with the Re drug, the tumor was visible on the first imaging on day 
44 after the inoculation of the cancer cells (S1-S2, 11/03 image). On day 51 (18/03), the tumor has 
disappeared in mice S2. On day 58 (25/03), there was no detectable tumor in the two mice, indicating 
a progressive regression of the tumor activity, even a long time after the interruption of the treatment 
with the Re-diselenoether complex (end of the treatment on day 36 after the inoculation of the cancer 
cells).   
 
 
Fig. 6 Imaging by bioluminescence in two mice (S1 and S2) treated by Re-diselenoether complex 
(from day 9 to day 36), on days 44 (11/03), 51 (18/03) and 58 (25/03). 
 
Incidence of Re-diselenoether complex on pulmonary metastases. The pulmonary metastases could be 
evaluated in 9 mice of each group (one mouse in each group died before day 42 and the number of 
pulmonary metastases was not measured). Seven suffering mice were sacrificed on day 65 (two from 
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group 1, one from group 2 and one from group 3: they all had pulmonary metastases). All other mice 
were sacrificed on day 67, corresponding to the end of the study. Finally, the presence of pulmonary 
metastases was noted in 9/9 mice in group 1; 5/9 in group 2 and 7/9 in group 3, with a mean number of 
metastases of 7.22 ± 2.47 in group 1; 3 ± 1.2 in group 2 and 3.57 ± 0.90 in group 3, as represented in 
Fig 7. The number of metastases was significantly greater in group 1 versus group 2 (p<0.05) and in 
group 1 versus group 3 (p<0.05), but there was no significant difference in group 2 versus group 3. 
 
 
 
 
Fig. 7 Pulmonary metastases. Group 1 mice treated by cisplatin, group 2 mice treated by Re (I) 
diselenoether complex, group 3, mice treated by Re (I)-diselenoether complex + cisplatin.  
 
Evaluation of the toxicity of Re-diselenoether complex. There was no sign of clinical toxicity in all 
groups according to the body weight of the mice as depicted in Fig 8. There was a death, but one in 
each group, between days 26 and 39  before the injection of cisplatin, that could be probably attributed 
to the pulmonary metastases (an autopsy was performed in 2 mice, revealing a great number of 
metastases).  Thus, the dose of 10 mg/kg/24 h of Re-diselenoether appeared to be well-tolerated.  
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Fig. 8  Mean weight of the mice after the inoculation of the cancer cells. Group 1: treatment by 
cisplatin (control); group 2: treatment with Re-diselenoether complex; group 3: treatment by Re-
diselenoether complex + cisplatin 
 
Biodistribution of Re-diselenoether complex in mice. The efficacy of the complex has been established 
in the animal experiment at a non-toxic dose of 10 mg/kg/d for four weeks, both on the primitive 
tumors and on the metastases. The biodistribution of Re and Se has already been published at this oral 
dose of 10 mg/kg/d versus 40 mg/kg/d of Re-diselenoether, and it was shown that the oral 
administration allows a good tissue uptake of Re and Se with a dose-effect [9] Mice were treated with 
Re-diselenoether at the dose of 10 mg/kg (corresponding to 3.3 ppm in Re and 2.8 ppm in Se), and 40 
mg/kg (13 ppm in Re and 11 ppm in Se), once-a-day for a period of four weeks. The distribution study 
revealed a Re concentration in the liver of 7.1 μmol/kg wet tissue (1.3 ppm) at the dose of 10 mg/kg 
and 19.8 μmol/kg wet tissue (3.4 ppm) at the dose of 40 mg/kg. Compared to the liver, lower 
concentrations were recorded in the kidney, namely 4.3 μmol/kg wet tissue (0.8 ppm) at the dose of 10 
mg/kg and 8.8 μmol/kg wet tissue (1.6 ppm) at the dose of 40 mg/kg. Regarding Se, the following 
concentrations (corrected from the essential Se found in the tissues of untreated mice) were recorded : 
in the liver, 12.9 μmol/kg wet tissue (1.0 ppm) at the dose of 10 mg/kg, 31.1 μmol/kg wet tissue (2.5 
ppm) at the dose of 40 mg/kg; in the kidney, 7.0 μmol/kg wet tissue (0.5 ppm) at the dose of 10 mg/kg 
and 8.8 μmol/kg wet tissue (0.7 ppm) at the dose of 40 mg/kg. These results deserve the following 
comments. A clear dose-effect of the drug was observed. Indeed, a 4-fold increase of the administered 
dose of Re-drug 1 (from 10 to 40 mg/kg/d) resulted in a 2.8-fold increase of the Re concentration in 
the liver and a 2.0-fold increase in the kidney. In the other hand, the Se/Re molar ratios in the liver 
were 1.8 at the dose of 10 mg/kg and 1.6 at the dose of 40 mg/kg. These ratios are quite close to the 
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2.0 Se/Re ratio found in the drug (two atoms of Se and one atom of Re per molecule). This 
observation suggests that the drug might be stored in the liver, more or less as it stands. However, in 
comparison with the liver, lower Se/Re ratios were recorded in the kidney (1.6 at the dose of 10 mg/kg 
and 1.0 at the dose of 40 mg/kg). These ratios revealed, as expected, a notable 
excretion/metabolization of the drug at the kidney level.  
 
Mechanisms of action of diselenoether complex 1. As both Re and Se are well taken up by tissues, it is 
possible to consider that these two elements will contribute to the antitumor effects by the combination 
of their different mechanisms of action. The main biological effects of Re are the formation of adducts 
(single or double strands) with proteins or DNA. These interactions have been extensively studied by 
Zobi et al.[21,22,27,28]. Re can bind to DNA adenine through the N1, N6 positions [29] or to guanine 
through the N7 position [30,31], resulting in Re/nucleotide 1:1 or Re/nucleotide 1:2 adducts. Reaction 
of Re-diselonether 5 with 9-methylguanine used as a simple model of DNA bases clearly established 
its ability to produced Re/nucleotide 1:1 or Re/nucleotide 1:2 adducts. In contrast to cisplatin, binding 
of Re drugs to one or two bases is reversible, the Re-adducts having proved less stable than Pt-
adducts. In fact, the formation of octahedral Re-adducts may be disfavored since they are generally 
more bulky and more sterically crowded than square-planar Pt-adducts. The possibility to administer 
the Re-diselenoether as a continuous oral administration will give it an advantage upon cisplatin, 
which generally needs to be administrated through a single injection.  
 
Although the anti-carcinogenic properties of Se are now well established, the modes of action of this 
element are still a subject of discussion, since they are very complex and not fully understood. 
However, we can emphasize on the mechanisms of action of Se on redox potential status, 
inflammation, immunity and cell signaling pathways including the consequences on cell apoptosis, 
DNA repair and metal detoxification, angiogenesis, metastasis and finally the effects on the tumor 
growth.  
 
Among the mechanisms of action of Se, its effects on the oxidative system are perhaps the most 
important. Se is mainly an anti-oxidant, via the selenoproteins, such as glutathione peroxidase (GPx) 
and thioredoxine reductase (TrxR). In fact, the existence of a systemic pro-oxidant status in patients 
with breast cancer is a well-established fact [32], depending on the stage of the disease [33] and of the 
molecular subtype [34]. A single systemic profile was found in patients with triple negative breast 
cancer with higher NO levels among subtypes [34].  An other antioxidant, the superoxide dismutase 
(SOD), has also been propose to fight against cell proliferation [35]. Ovarian cancer patients resistant 
to treatments by carboplatin/paclitaxel have a lower level of antioxidant response activation compared 
to sensitive patients [36], and to restore the oxidative status could increase the efficacy of anticancer 
cytotoxic drugs. In contrast, the common cytotoxic agents are pro-oxidant drugs like paclitaxel and 
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doxorubicin [37]. In this respect,  high concentrations of Se may produce reactive oxygen species 
(ROS) and lead to apoptotic cell death by inducing oxidation and cross-linking of protein thiol groups 
essential for cell survival [38]. According to Jamier et al. [39], selenium-based agents could turn the 
oxidizing redox environment present in certain cancer cells into a lethal cocktail of reactive species 
that push these cells over a critical redox threshold and ultimately kill them through apoptosis. This 
kind of toxicity is highly selective: normal, healthy cells remain largely unaffected, since changes to 
their naturally low levels of oxidizing species produce little effect. The balance between pro-oxidative 
and anti-oxidative effects of Se compounds is still unclear, but it is obvious that the redox potential of 
cancer cells needs to be taken into account to evaluate the treatments by Se compounds. A very 
interesting display thiol-proteomics approach to characterize global redox modification of proteins by 
Se has been proposed by Park et al [40].  
 
As a second mechanism of action, Se, mainly as selenoproteins, plays an important role in 
inflammation [41-42]. There is a strong interaction between inflammation and cancer, and platinum 
drugs have even been designed with the aim of targeting NK-KappaB signaling pathways [43]. Se 
compounds could have an impact on the inflammatory status through the inactivation of NF-kappa B 
[44-45]. The interactions between cancer stem cells (CSC) and inflammation are also of a great 
importance [46] for the development of cancer and its resistance to therapeutic agents. Due to its effect 
on inflammation, we could expect a role of the Re-diselenoether complex in the growth and activity of 
CSC.   
 
Studies with Se-compounds indicated that Se may also have positive effects on immune response [47-
49], or more specifically on the activity on NK cells [50-52]. Methylselenol ,which is the active 
metabolite of organic Se compounds, has already been shown to regulate the expression of NKG2D 
ligands by MDA-MB231 and MCF-7 cells [53]. These ligands are involved in the recognition of the 
malignant cells by natural killer (NK) cells [54-59]. Selenoproteins also mediate T cell immunity 
through an antioxidant mechanism [60]. Se plays also an important role as an anti-inflammatory agent 
by tightly regulating the expression of pro-inflammatory genes in immune cells [61]. 
 
The role of Se compounds on signaling pathways involved in the development of cancer may be the 
most modern aspect to consider their therapeutic impact. Seleno-compounds are thought to modulate 
several kinases. The PI3K/AKT pathway appears as a common target for seleno compounds, but they 
may modulate different kinases at the same time and their effectiveness varies depending on the 
genetic background of the tumor cells [62]. All the seleno-compounds did not exhibit kinase inhibitory 
activity. The type of kinase inhibition greatly depends on the selenium derivative. The kinases 
modulated by sulfur and selenium derivatives include MAP, ERK, JNK, Akt, Cdc2, Cyclin B1 and 
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Cdc25c amongst others [18]. Therefore, there will be a great need for testing the Re-diselenoether 
complex on different tyrosine and serine/threonine kinases, especially in breast cancer cell lines.  
 
Due to the molecular and biological effects of Se and selenoproteins, there is an expected benefit in 
cancer patients, not only on the primitive malignant tumor growth, but also on angiogenesis [63-64] 
and metastasis [65]. However, the exact schedule of treatment needs to be clarified for each cancer 
disease, with the help of different markers that remain to be better identified. Plasma Se levels, which 
have already been investigated in a cohort of breast cancer patients [66], could be useful to monitor the 
therapy. Whatever the modes of action of these elements, one can argue that there existed a synergistic 
effect between Re and Se partners accounting for the remarkable, promising antitumor activity of 
Re(I)- diselenoether complex, already patented in Europe [67].  
 
 
In summary, Re-diselenoether complex is a promising new metal-based anticancer drug for the 
treatment of patients with metastatic breast cancer. It proved to efficiently reduce tumor cell division 
in vitro at a low concentration of 10 M. It may be orally administered, and the recommended dose is 
a non-toxic dose of 10 mg/kg/d for a treatment of at least four weeks. The efficacy may result from the 
activity of both Re and Se on key targets of the cancer cells and their microenvironment. Among the 
mechanisms of action, we confirmed the effects on DNA, due to the Re atom. The effects on the 
immune system, the redox status, the inflammation and cell signaling pathways attributed to the Se 
component will be investigated in further studies with models of hormone-independent (MDA-
MB231) and hormone-sensitive (MCF-7) metastatic breast cancer. 
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Supplementary material 
Table I: Evolution of the mice tumor volume, in mm
3
 (mean ± SEM) after IP administration of 
cisplatin (group 1), oral administration of Re (I)- diselenoether complex with the dose of 10 mg/kg/d 
(group 2), oral administration of Re (I)- diselenoether with the dose of 10 mg/kg/d + IP injection of 
cisplatin (group 3).  
 
Days Group 1 Group 2 Group 3 
0 0 ± 0 0 ± 0 0 ± 0 
3 1 ± 2 0 ± 0 1 ± 2 
6 1 ± 2 0 ± 0 1 ± 3 
9 3 ± 3 3 ± 4  3 ± 5 
12 5 ± 6 4 ± 4 3 ± 6 
16 6 ± 9 4 ± 6 5 ± 8 
24 26 ± 21 9 ± 13 11 ± 16 
27 20 ± 27 12 ± 15 13 ± 18 
31 28 ± 40 17 ± 24 17 ± 23 
33 31 ± 40 19 ± 22 19 ± 28 
37 41 ± 48 16 ± 20 21 ± 25 
40 55 ± 56 16 ± 20 28 ± 33 
44 62 ± 67 20 ± 27 35 ± 41 
47 70 ± 108 7 ± 15 39 ± 63 
52 102 ± 30 7 ± 2 101 ± 21 
56 114 ± 32 6 ± 3 105 ± 21 
59 114 ± 30 5 ± 2 127 ± 28 
62 122 ± 34 5 ± 3 160 ± 34 
67 138 ± 38 5 ± 3 183 ± 36 
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Supp 1 : Structures of the observed ions in mass spectrum 
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